Literature DB >> 22531276

Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.

María C Sádaba1, John Tzartos, Carlos Paíno, Mercedes García-Villanueva, José C Alvarez-Cermeño, Luisa M Villar, Margaret M Esiri.   

Abstract

BACKGROUND: Recent findings support the important role of antibodies in multiple sclerosis (MS) physiopathology. Thus, local IgG synthesis is a hallmark of the disease, and intrathecal IgM synthesis associates with a poor disease outcome.
METHODOLOGY: The aim of this study was to investigate the presence of IgM and IgG in demyelinating lesions using high sensitivity immunohistochemistry techniques in necropsies from fourteen MS patients, four controls without neurological disease and four cases with non MS CNS inflammatory disease.
RESULTS: IgG and IgM were absent in controls. Conversely, we found IgM in about 50% and IgG in 75% of MS patients. The presence of IgM and IgG antibodies was independent of disease duration, clinical disease type or lesion stage. IgM and IgG were present in acute, chronic active and chronic inactive lesions. Double immunofluorescence showed that IgM and IgG were detected on axons and oligodendrocytes in demyelinated areas. Moreover, we observed immunoglobulin deposits on oligodendrocytes in NAWM in some cases. IgG and IgM colocalized with complement C3b on demyelinated axons and oligodendrocytes and antibody-antigen immunocomplexes were detected in foamy macrophages in active lesion areas. These findings were absent from cases of non-neurological disease and cases with non-MS CNS inflammatory disease. SIGNIFICANCE OF THE STUDY: These observations provide further evidence on the role of antibodies, complement and macrophages in plaque development, and strongly suggest they can induce axonal injury, an important cause of disability in MS. They may provide novel therapeutic strategies to limit tissue degeneration in the disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531276     DOI: 10.1016/j.jneuroim.2012.03.020

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  18 in total

1.  Multiple sclerosis: Genetic variability affects CNS IgG production in MS.

Authors:  Jose C Álvarez-Cermeño; Luisa M Villar
Journal:  Nat Rev Neurol       Date:  2015-04-14       Impact factor: 42.937

Review 2.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 3.  The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Authors:  Rui Li; Amit Bar-Or
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

4.  Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.

Authors:  Nicola Capasso; Raffaele Palladino; Vincenza Cerbone; Antonio Luca Spiezia; Bianca Covelli; Antonia Fiore; Roberta Lanzillo; Antonio Carotenuto; Maria Petracca; Lucia Stanziola; Giulia Scalia; Vincenzo Brescia Morra; Marcello Moccia
Journal:  J Neurol       Date:  2022-09-01       Impact factor: 6.682

5.  Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

Authors:  A J Ligocki; W H Rounds; E M Cameron; C T Harp; E M Frohman; A M Courtney; S Vernino; L G Cowell; B Greenberg; N L Monson
Journal:  Genes Immun       Date:  2013-04-18       Impact factor: 2.676

Review 6.  Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.

Authors:  Zahra Alirezaei; Mohammad Hossein Pourhanifeh; Sarina Borran; Majid Nejati; Hamed Mirzaei; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.590

7.  Neurofilament light as an immune target for pathogenic antibodies.

Authors:  Fabiola Puentes; Baukje J van der Star; Stephanie D Boomkamp; Markus Kipp; Louis Boon; Isabel Bosca; Joel Raffel; Sharmilee Gnanapavan; Paul van der Valk; Jodie Stephenson; Susan C Barnett; David Baker; Sandra Amor
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

8.  Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis.

Authors:  Ursula Muñoz; Cristina Sebal; Esther Escudero; Margaret Esiri; John Tzartos; Carolyn Sloan; Mari Cruz Sadaba
Journal:  Cell Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.046

9.  Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype.

Authors:  Adahir Labrador-Garrido; Marta Cejudo-Guillén; Rebecca Klippstein; Erwin J De Genst; Laura Tomas-Gallardo; María M Leal; Javier Villadiego; Juan J Toledo-Aral; Christopher M Dobson; David Pozo; Cintia Roodveldt
Journal:  Immun Inflamm Dis       Date:  2014-12-05

Review 10.  The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Samuel S Duffy; Justin G Lees; Gila Moalem-Taylor
Journal:  Mult Scler Int       Date:  2014-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.